Latest Breaking News On - Interim chief medical - Page 1 : vimarsana.com

Multiple Abstracts Highlighting Vir Biotechnology s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024

Multiple Abstracts Highlighting Vir Biotechnology s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

France generalAndrea cathcartCarey hwangSnehav guptaTarik asselahAlnylam pharmaceuticals incUniversity of parisClinical researchExchange commissionVir biotechnology incVir biotechnologyEuropean associationLiver diseasesSenior vice presidentInterim chief medicalViral hepatitis

Vir Biotechnology, Inc : Multiple Abstracts Highlighting Vir Biotechnology s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024

- Company to present important new data from the Phase 2 SOLSTICE chronic hepatitis delta trial - - Conference call scheduled for June 5, 2024, at 6:00 a.m. ET 12:00 p.m. CEST - Vir Biotechnology

France generalSnehav guptaCarey hwangCarly scadutoAndrea cathcartRichard lepkeTarik asselahAlnylam pharmaceuticals incUniversity of parisClinical researchExchange commissionVir biotechnology incEuropean associationLiver diseasesSenior vice presidentInterim chief medical

Faron s Financial Statement Release January 1 to December

TURKU, Finland and BOSTON, March 13, 2024 (GLOBE NEWSWIRE) Faron Pharmaceuticals Ltd. (

United statesFred hutchinson cancer research centerFrank armstrongBirge bernsJuha karttunenLindsey nevilleGregoryb brownJo turnerDavid daleyJames obrienAnne whitakerLeopoldo zambelettiChristine rothMarkku jalkanenChristopher goldenMary jane elliott

Faron s Financial Statement Release January 1 to December 31, 2023 -March 13, 2024 at 03:01 am EDT

TURKU, Finland and BOSTON, March 13, 2024 Faron Pharmaceuticals Ltd. , a clinical-stage biopharmaceutical company focused on tackling cancers via novel myeloid cell targeted immunotherapies,.

United statesFred hutchinson cancer research centerJo turnerChristine rothJames obrienLeopoldo zambelettiSandy jamiesonJuha karttunenDavid daleyGregoryb brownMary jane elliottMarkku jalkanenBirge bernsChristopher goldenLindsey nevilleAnne whitaker

Fulcrum Therapeutics, Inc (NASDAQ:FULC) Q4 2023 Earnings Call Transcript

Fulcrum Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.4, expectations were $-0.44.

Michael burryIain fraserJoseph schwartzAlex sapirMatthew bieglerCorinne johnsonAlan mussoFulcrum therapeutics incGoldman sachsExchange commissionFulcrum therapeuticsCall transcript februaryFulcrum therapeutics fourth quarterFull yearBusiness update conferencePrivate security litigation reform act